Secondary prevention trials in Alzheimer disease: The challenge of identifying a meaningful end point

JAMA Neurology

Volumn 71, Issue 8, 2014, Pages 947-949

  Kryscio, Richard J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CLINICAL EFFECTIVENESS; DIGIT SYMBOL SUBSTITUTION TEST SCORE; EDITORIAL; EXECUTIVE FUNCTION; HUMAN; INCIDENCE; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; OXIDATION KINETICS; POSITRON EMISSION TOMOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; SCORING SYSTEM; SECONDARY PREVENTION; THERAPY DELAY; VALIDATION PROCESS; WECHSLER MEMORY SCALE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; FEMALE; MALE; METABOLISM; NEUROPSYCHOLOGICAL TEST; STANDARDS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS;

EID: 84905963790     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1120     Document Type: Editorial

References (10)

1. Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am. 2013;97(3):439-457.
2. Donohue MC, Sperling RA, Salmon DP, et al Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease Cooperative Study. The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline [published online June 2, 2014]. JAMA Neurol. doi:10.1001/jamaneurol.2014.803.
3. Kryscio RJ, Mendiondo MS, Schmitt FA, MarkesberyWR. Designing a large prevention trial: statistical issues. Stat Med. 2004;23(2):285-296. (Pubitemid 38100641)
4. Carrillo MC, Brashear HR, Logovinsky V, et al. Can we prevent Alzheimer's disease? secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement. 2013;9(2):123-131.e1.
5. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc. 2008;14(2):266-278. (Pubitemid 351280005)
6. Crane PK, Carle A, Gibbons LE, et al Alzheimer's Disease Neuroimaging Initiative. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6(4):502-516.
7. Xiong C, van Belle G, Chen K, et al. Combining multiple markers to improve the longitudinal rate of progression-application to clinical trials on the early stage of Alzheimer's disease. Stat Biopharm Res. 2013;5(1):10.1080/ 19466315.2012.756662.
8. Ard MC, Edland SD. Power calculations for clinical trials in Alzheimer's disease. J Alzheimers Dis. 2011;26(suppl 3):369-377.
9. Schneider LS, Kennedy RE, Cutter GR; Alzheimer's Disease Neuroimaging Initiative. Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2010;6(5):367-377.
10. Beckett LA, Harvey DJ, Gamst A, et al; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010;6(3):257-264.